Usmani Highlights the Role of Bispecific Antibodies in Relapsed/Refractory Multiple Myeloma

Dr Usmani discusses the integration of elranatamab, talquetamab, and telcistamab into the management of relapsed/refractory multiple myeloma, common adverse effects and recommended supportive care measures, and ongoing research that may help clarify their role in the paradigm.